Rep. David Taylor Buys Eli Lilly and Company (NYSE:LLY) Stock

Key Points

• Representative David Taylor purchased shares of Eli Lilly and Company (NYSE:LLY) valued between $15,001 and $50,000 on August 14th, 2025.
• Eli Lilly reported a quarterly EPS of $6.31, exceeding estimates, with revenue increasing by 37.6% year-over-year, bringing in $15.56 billion.
• The company recently declared a quarterly dividend of $1.50, which translates to a 0.8% annual yield, with the ex-dividend date set for August 15th.

Representative David Taylor (R-Ohio) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on September 02nd, the Representative disclosed that they had bought between $15,001 and $50,000 in Eli Lilly and Company stock on August 14th. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) - DAVE" account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Marathon Petroleum NYSE: MPC on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Vertex Pharmaceuticals NASDAQ: VRTX on 8/7/2025.
• Sold $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 8/7/2025.

Eli Lilly and Company Price Performance

NYSE LLY traded up $4.39 on Thursday, reaching $742.22. The company's stock had a trading volume of 2,419,935 shares, compared to its average volume of 4,141,353. The firm has a market cap of $702.48 billion, a PE ratio of 48.51, a price-to-earnings-growth ratio of 1.02 and a beta of 0.47. The business has a 50-day moving average price of $745.91 and a 200 day moving average price of $783.42. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $943.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the company earned $3.92 earnings per share. The company's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is 39.22%.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently added to or reduced their stakes in LLY. Corient IA LLC bought a new stake in Eli Lilly and Company in the first quarter worth approximately $570,000. LS Investment Advisors LLC lifted its stake in Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after acquiring an additional 40 shares in the last quarter. Prism Advisors Inc. purchased a new stake in Eli Lilly and Company in the 1st quarter valued at about $207,000. Hemington Wealth Management lifted its holdings in Eli Lilly and Company by 14.4% during the first quarter. Hemington Wealth Management now owns 985 shares of the company's stock worth $813,000 after acquiring an additional 124 shares during the period. Finally, Duquesne Family Office LLC boosted its holdings in shares of Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after buying an additional 32,640 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LLY. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price objective for the stock from $675.00 to $700.00 in a research note on Wednesday, August 27th. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Finally, Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $950.17.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 in the last three months. Corporate insiders own 0.14% of the company's stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.